Understanding pathways to stimulant use: a mixed-methods examination of the individual, social and cultural factors shaping illicit stimulant use across Europe (ATTUNE): study protocol.
amphetamine-type stimulants
drug use trajectory
life course
study protocol
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
10 08 2019
10 08 2019
Historique:
entrez:
12
8
2019
pubmed:
12
8
2019
medline:
2
9
2020
Statut:
epublish
Résumé
Amphetamine-type stimulants (ATS) including amphetamine, methylenedioxymethamphetamine/'ecstasy', methamphetamine, synthetic cathinones and 'Ritalin' are the second most commonly used illicit drugs globally. Yet, there is little evidence on which factors are associated with the development of different patterns of ATS use over the life course. This study aims to examine which individual, social and environmental factors shape different pathways and trajectories of ATS consumption. The study will be conducted in five European countries: Germany, the Netherlands, Poland, Czech Republic and the UK. We will use a sequential mixed-methods study design to investigate the multiple factors (familial, social and occupational situation, critical life events, general risk behaviour, mental and physical health, satisfaction with life) that shape individual ATS use pathways. A systematic literature review will be performed to provide an overview of the current academic literature on the topic. In module 1, qualitative semistructured interviews (n=ATS users and non-users) will be conducted to explore individual experiences of, and perspectives on, dynamics of change in stimulant consumption patterns. In module 2, structured questionnaires (n=2000 ATS users and non-users) will be administered via tablet computers to validate and enhance the generalisability of the interview findings. Data integration will take place at two key points. First, during the study, where the findings from the first qualitative interviews will inform the design of the structured questionnaire. Second, at the end of the study, where mixed methods data will be brought together to generate an in-depth, contextualised understanding of the research topic. The study has been approved by the respective responsible ethics committee in each participating country. Data will be treated confidentially to ensure participants' anonymity. Findings will be disseminated in peer-reviewed scientific journals, national and international conferences, and in briefings for policy and practice.
Identifiants
pubmed: 31401601
pii: bmjopen-2019-029476
doi: 10.1136/bmjopen-2019-029476
pmc: PMC6701668
doi:
Substances chimiques
Central Nervous System Stimulants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e029476Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: UV received a speaker’s honoraria and travelling expenses from Mundipharma GmbH. AOD was funded by an NIHR School for Primary Care Research Fellowship between October 2015 and September 2017.
Références
J Addict Dis. 2002;21(1):45-60
pubmed: 11831499
Depress Anxiety. 2003;18(2):76-82
pubmed: 12964174
Drug Alcohol Depend. 2003 Dec 11;72(3):279-86
pubmed: 14643945
Subst Use Misuse. 2005;40(9-10):1427-41
pubmed: 16048826
J Ethn Subst Abuse. 2005;4(2):9-38
pubmed: 16275633
J Pers Assess. 1985 Feb;49(1):71-5
pubmed: 16367493
Addiction. 2006 Aug;101(8):1143-52
pubmed: 16869844
Drug Alcohol Depend. 2007 Oct 8;90(2-3):135-44
pubmed: 17398040
J Psychoactive Drugs. 2007 Jun;39(2):103-13
pubmed: 17703705
J Adolesc Health. 2008 Jan;42(1):36-42
pubmed: 18155028
Drug Alcohol Rev. 2008 May;27(3):243-52
pubmed: 18368605
J Psychoactive Drugs. 2009 Mar;41(1):19-26
pubmed: 19455906
Soc Sci Med. 2009 Oct;69(8):1204-10
pubmed: 19700232
Neuropsychobiology. 2009;60(3-4):137-47
pubmed: 19893331
Subst Use Misuse. 2010;45(1-2):116-33
pubmed: 20025442
Annu Rev Public Health. 2010;31:385-98
pubmed: 20070191
J Ethnogr Qual Res. 2009;3(3):139-151
pubmed: 21552386
Qual Health Res. 2012 Oct;22(10):1435-43
pubmed: 22829486
Drug Alcohol Depend. 2013 Aug 1;131(3):278-83
pubmed: 23312339
Addiction. 2013 Oct;108(10):1809-17
pubmed: 23668641
Glob Public Health. 2013;8(5):552-69
pubmed: 23679831
Drug Alcohol Depend. 2013 Oct 1;132(3):665-73
pubmed: 23683794
Adm Policy Ment Health. 2015 Sep;42(5):533-44
pubmed: 24193818
Health Promot Perspect. 2011 Dec 20;1(2):86-94
pubmed: 24688904
Int J Drug Policy. 2015 Dec;26(12):1171-6
pubmed: 26298332
Qual Health Res. 2016 Nov;26(13):1753-1760
pubmed: 26613970
Cochrane Database Syst Rev. 2016 Sep 29;9:CD011866
pubmed: 27684277
J Ethn Subst Abuse. 2018 Jan-Mar;17(1):32-49
pubmed: 29035155
Addiction. 2019 Jan;114(1):24-47
pubmed: 30176077
Lancet Psychiatry. 2018 Dec;5(12):987-1012
pubmed: 30392731
JAMA. 1984 Oct 12;252(14):1905-7
pubmed: 6471323
Addiction. 1995 May;90(5):607-14
pubmed: 7795497
Science. 1977 Apr 8;196(4286):129-36
pubmed: 847460
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608